Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2014-01-14 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-01-14 English
PRIMARY DOCUMENT
Director's Dealing
2014-01-14 English
PRIMARY DOCUMENT
Director's Dealing
2014-01-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the filing includes an attached press release dated January 13, 2014, but does not contain detailed financial statements or substantive financial data itself. The document length is only 2292 characters, which is quite short and consistent with an announcement rather than a full report. There is no indication that this is an earnings release, annual report, or other detailed financial report. The document is primarily an announcement of an event or press release, typical of an 8-K filing. According to the classification rules, such filings fall under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2014-01-13 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 13, 2014, by Galectin Therapeutics Inc. It primarily discloses that the company has posted a corporate presentation on its website summarizing its business. The document explicitly states that the presentation is being furnished and not filed, and the 8-K itself does not contain detailed financial statements or substantive financial data. The length of the document is 2978 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is the announcement of a corporate presentation, which aligns with the category of Investor Presentation (IP). Therefore, the document should be classified as an Investor Presentation (IP) filing type.
2014-01-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates that the filing includes an attached press release dated January 10, 2014, but the document itself is short (2296 characters) and primarily serves as a notification of the press release. There are no financial statements or detailed financial data included in the text. The document is not an annual or quarterly report, nor is it a transcript or management discussion. It is a regulatory filing used to announce an event or press release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-01-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.